Literature DB >> 8706593

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.

C J Rosen1, C R Kessenich.   

Abstract

The bisphosphonates are a class of synthetic compounds used in the treatment of various metabolic bone diseases, including hypercalcaemia of malignancy, Paget's disease, postmenopausal osteoporosis and corticosteroid-induced bone loss. Although there have been numerous studies comparing first, second and third generation bisphosphonates with placebo, there has been a paucity of comparative research investigating the effectiveness of these substances with other pharmacological agents. Still, the available evidence indicates that the bisphosphonates are well tolerated and effective therapeutic agents for various metabolic bone diseases. It seems certain that within the next 5 years, this class of drugs will emerge as one of the foremost options for treating Paget's disease and osteoporosis.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8706593     DOI： 10.2165/00003495-199651040-00003

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  67 in total

1.  Long-lasting dermatological lesions after tiludronate therapy.

Authors:  C Roux; V Listrat; B Villette; M Lessana-Leibowitch; D Ethgen; C Pelissier; M Dougados; B Amor
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

Review 2.  Treatment of osteoporoses by manipulation of coherent bone cell populations.

Authors:  H M Frost
Journal:  Clin Orthop Relat Res       Date:  1979-09       Impact factor: 4.176

3.  Design of the Fracture Intervention Trial.

Authors:  D M Black; T F Reiss; M C Nevitt; J Cauley; D Karpf; S R Cummings
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

4.  Paget's disease of bone: five regimens of pamidronate treatment.

Authors:  T Pepersack; R Karmali; C Gillet; D François; M Fuss
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

5.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors:  S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal:  Am J Med       Date:  1993-12       Impact factor: 4.965

6.  Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.

Authors:  J Adachi; A Cranney; C H Goldsmith; W G Bensen; F Bianchi; A Cividino; G L Craig; E Kaminska; R J Sebaldt; A Papaioannou
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

7.  Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.

Authors:  A Struys; A A Snelder; H Mulder
Journal:  Am J Med       Date:  1995-09       Impact factor: 4.965

8.  Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  I R Reid; A R King; C J Alexander; H K Ibbertson
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

9.  Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone.

Authors:  R D Altman
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

10.  Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.

Authors:  M Rossini; D Gatti; N Zamberlan; V Braga; R Dorizzi; S Adami
Journal:  J Bone Miner Res       Date:  1994-11       Impact factor: 6.741
View more
  8 in total

Review 1.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

Review 2.  Bone as an effect compartment : models for uptake and release of drugs.

Authors:  David Stepensky; Lilach Kleinberg; Amnon Hoffman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Apoptosis in interface membranes of aseptically loose total hip arthroplasty.

Authors:  O L Huk; D J Zukor; W Ralston; A Lisbona; A Petit
Journal:  J Mater Sci Mater Med       Date:  2001-07       Impact factor: 3.896

4.  Effect of renal function on risedronate pharmacokinetics after a single oral dose.

Authors:  D Y Mitchell; J V St Peter; R A Eusebio; K A Pallone; S C Kelly; D A Russell; J D Nesbitt; G A Thompson; J H Powell
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

5.  Alendronate inhibits periprosthetic bone loss around uncemented femoral components.

Authors:  Takashi Nishioka; Shoji Yagi; Tadashi Mitsuhashi; Masafumi Miyamoto; Tatsuya Tamura; Toru Kobayashi; Tetsuya Enishi
Journal:  J Bone Miner Metab       Date:  2007-04-20       Impact factor: 2.626

6.  Effect of bisphosphonates on the stimulation of macrophages by alumina ceramic particles: a comparison with ultra-high-molecular-weight polyethylene.

Authors:  Alain Petit; Fackson Mwale; John Antoniou; David J Zukor; Olga L Huk
Journal:  J Mater Sci Mater Med       Date:  2006-07       Impact factor: 4.727

Review 7.  Bisphosphonate therapy for children and adolescents with secondary osteoporosis.

Authors:  L Ward; A C Tricco; P Phuong; A Cranney; N Barrowman; I Gaboury; F Rauch; P Tugwell; D Moher
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

8.  Bisphosphonate Treatment in a Patient Affected by MPS IVA with Osteoporotic Phenotype.

Authors:  Albina Tummolo; Orazio Gabrielli; Alberto Gaeta; Maristella Masciopinto; Lucia Zampini; Luigi Michele Pavone; Paola Di Natale; Francesco Papadia
Journal:  Case Rep Med       Date:  2013-11-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.